According to SNS Insider, the global RNAi Technology Market was valued at USD 3.02 billion in 2024 and is projected to reach USD 9.03 billion by 2032, expanding at a CAGR of 14.68% over 2025–2032. RNA ...

Potential of RNAi therapies - new analysis showing R&D, trends, and revenue prospects Where are RNA interference based medicines going? For those treatments you can get new sales predictions and ...

4月19日に中外製薬は、グループ会社であるスイスのロシュからジレベシランという高血圧症治療薬候補の日本での商業化権を獲得したと発表した。ジレベシランは現在、既存の高血圧症に対する飲み薬ではコントロールが難しい患者を対象に、6カ月に1回 ...

米アルナイラム・ファーマシューティカルズのイボンヌ・グリーンストリートCEO（写真=柴仁人） リボヌクレオチドという ...

We describe a protocol for performing RNA interference (RNAi) screens in Caenorhabditis elegans in liquid culture in 96-well plates. The procedure allows a single researcher to set-up and score RNAi ...

RNAi is a natural process that was first characterized in full by Andrew Fire and Craig Mellow in 1998. Since then, RNAi has become a workhorse method for studies of individual gene function. More ...

A Cornucopia of siRNA- and RNAi-based Therapeutics in Development Show Promise Researchers from academia and industry will present the latest developments in the application of interference RNA (RNAi) ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Biotherapeutics, a division of Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the presentation of new ...

RNAi (Ribonucleic Acid Interference) a system in live cells to keep a check on the active genes is the next promising technology in the field of biotechnology. The major classes of RNAi are micro RNA ...